The purpose of this study is to determine whether acetazolamide are effective to reduce the length of mechanical ventilation in decompensated Chronic Obstructive Pulmonary Disease (COPD) patients developing pure or mixed metabolic alkalosis.
The purpose of this study is to determine whether acetazolamide is effective to reduce the length of mechanical ventilation in decompensated COPD patients developing pure or mixed metabolic alkalosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
380
Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
Placebo
Clinical Research Unit, European Georges Pompidou Hospital, Assistance Publique - Hôpitaux de Paris
Paris, France
length of invasive mechanical ventilation
Time frame: within the first 28 days after intubation
Length of weaning from mechanical ventilation
data retrieved once, at the extubation or at the end of invasive ventilation in the tracheotomy
Time frame: once at the extubation or at day 28
weaning success
Data collected once at the end of ICU stay or at Day 28
Time frame: once at the end of ICU stay or at Day 28
numbers of nosocomial infections
data retrieved every day, until extubation or at the end of invasive ventilation in the tracheotomy
Time frame: every day during 28 days
length of ICU stay
Data collected once at the end of ICU stay or at Day 28
Time frame: once at the end of ICU stay or at Day 28
ICU mortality
Data collected once at the end of ICU stay or at Day 28
Time frame: once at the end of ICU stay or at Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.